| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10765640 | SCILEX PHARMS INC | Non-aqueous patch |
May, 2031
(7 years from now) | |
| US9931403 | SCILEX PHARMS INC | Non-aqueous patch |
May, 2031
(7 years from now) | |
| US10765749 | SCILEX PHARMS INC | Non-aqueous patch |
May, 2031
(7 years from now) | |
| US11278623 | SCILEX PHARMS INC | Non-aqueous patch |
May, 2031
(7 years from now) | |
| US9925264 | SCILEX PHARMS INC | Non-aqueous patch |
May, 2031
(7 years from now) | |
| US9283174 | SCILEX PHARMS INC | Non-aqueous patch |
May, 2031
(7 years from now) | |
Ztlido is owned by Scilex Pharms Inc.
Ztlido contains Lidocaine.
Ztlido has a total of 6 drug patents out of which 0 drug patents have expired.
Ztlido was authorised for market use on 28 February, 2018.
Ztlido is available in patch;topical dosage forms.
Ztlido can be used as method for relieving the pain associated with post-herpetic neuralgia.
The generics of Ztlido are possible to be released after 10 May, 2031.
Drugs and Companies using LIDOCAINE ingredient
Market Authorisation Date: 28 February, 2018
Treatment: Method for relieving the pain associated with post-herpetic neuralgia
Dosage: PATCH;TOPICAL
ZTLIDO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic